Highlights
The global Genital Herpes Research and Development Pipeline market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Genital Herpes Research and Development Pipeline is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Genital Herpes Research and Development Pipeline is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Genital Herpes Research and Development Pipeline in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Genital Herpes Research and Development Pipeline include AiCuris GmbH & Co. KG, AlphaVax, Inc., Foamix Pharmaceuticals Ltd., Genocea Biosciences, Inc., GenVec, Inc., Immune Design Corp., Immunovaccine, Inc., Mymetics Corporation and NanoBio Corporation, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Genital Herpes Research and Development Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genital Herpes Research and Development Pipeline.
The Genital Herpes Research and Development Pipeline market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Genital Herpes Research and Development Pipeline market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genital Herpes Research and Development Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
AiCuris GmbH & Co. KG
AlphaVax, Inc.
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Immune Design Corp.
Immunovaccine, Inc.
Mymetics Corporation
NanoBio Corporation
NanoViricides, Inc.
PaxVax
Profectus BioSciences, Inc.
Sanofi Pasteur SA
Spider Biotech
Starpharma Holdings Limited
Vaccibody AS
Vaxart, Inc.
Vical Incorporated.
Segment by Type
Acyclovir
Aspidasept
G-103
GEN-003
GV-2207
HerpeCide-I
HSV-529
Pritelivir
SB-105A10
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Genital Herpes Research and Development Pipeline companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Genital Herpes Research and Development Pipeline 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Acyclovir
1.2.3 Aspidasept
1.2.4 G-103
1.2.5 GEN-003
1.2.6 GV-2207
1.2.7 HerpeCide-I
1.2.8 HSV-529
1.2.9 Pritelivir
1.2.10 SB-105A10
1.3 麻豆原创 by Application
1.3.1 Global Genital Herpes Research and Development Pipeline 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Genital Herpes Research and Development Pipeline 麻豆原创 Perspective (2018-2029)
2.2 Genital Herpes Research and Development Pipeline Growth Trends by Region
2.2.1 Global Genital Herpes Research and Development Pipeline 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Genital Herpes Research and Development Pipeline Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Genital Herpes Research and Development Pipeline Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Genital Herpes Research and Development Pipeline 麻豆原创 Dynamics
2.3.1 Genital Herpes Research and Development Pipeline Industry Trends
2.3.2 Genital Herpes Research and Development Pipeline 麻豆原创 Drivers
2.3.3 Genital Herpes Research and Development Pipeline 麻豆原创 Challenges
2.3.4 Genital Herpes Research and Development Pipeline 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genital Herpes Research and Development Pipeline Players by Revenue
3.1.1 Global Top Genital Herpes Research and Development Pipeline Players by Revenue (2018-2023)
3.1.2 Global Genital Herpes Research and Development Pipeline Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Genital Herpes Research and Development Pipeline 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Genital Herpes Research and Development Pipeline Revenue
3.4 Global Genital Herpes Research and Development Pipeline 麻豆原创 Concentration Ratio
3.4.1 Global Genital Herpes Research and Development Pipeline 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genital Herpes Research and Development Pipeline Revenue in 2022
3.5 Genital Herpes Research and Development Pipeline Key Players Head office and Area Served
3.6 Key Players Genital Herpes Research and Development Pipeline Product Solution and Service
3.7 Date of Enter into Genital Herpes Research and Development Pipeline 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Genital Herpes Research and Development Pipeline Breakdown Data by Type
4.1 Global Genital Herpes Research and Development Pipeline Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Genital Herpes Research and Development Pipeline Forecasted 麻豆原创 Size by Type (2024-2029)
5 Genital Herpes Research and Development Pipeline Breakdown Data by Application
5.1 Global Genital Herpes Research and Development Pipeline Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Genital Herpes Research and Development Pipeline Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Genital Herpes Research and Development Pipeline 麻豆原创 Size (2018-2029)
6.2 North America Genital Herpes Research and Development Pipeline 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2018-2023)
6.4 North America Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Genital Herpes Research and Development Pipeline 麻豆原创 Size (2018-2029)
7.2 Europe Genital Herpes Research and Development Pipeline 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2018-2023)
7.4 Europe Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genital Herpes Research and Development Pipeline 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Genital Herpes Research and Development Pipeline 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Genital Herpes Research and Development Pipeline 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Genital Herpes Research and Development Pipeline 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Genital Herpes Research and Development Pipeline 麻豆原创 Size (2018-2029)
9.2 Latin America Genital Herpes Research and Development Pipeline 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genital Herpes Research and Development Pipeline 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Genital Herpes Research and Development Pipeline 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Genital Herpes Research and Development Pipeline 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AiCuris GmbH & Co. KG
11.1.1 AiCuris GmbH & Co. KG Company Detail
11.1.2 AiCuris GmbH & Co. KG Business Overview
11.1.3 AiCuris GmbH & Co. KG Genital Herpes Research and Development Pipeline Introduction
11.1.4 AiCuris GmbH & Co. KG Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.1.5 AiCuris GmbH & Co. KG Recent Development
11.2 AlphaVax, Inc.
11.2.1 AlphaVax, Inc. Company Detail
11.2.2 AlphaVax, Inc. Business Overview
11.2.3 AlphaVax, Inc. Genital Herpes Research and Development Pipeline Introduction
11.2.4 AlphaVax, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.2.5 AlphaVax, Inc. Recent Development
11.3 Foamix Pharmaceuticals Ltd.
11.3.1 Foamix Pharmaceuticals Ltd. Company Detail
11.3.2 Foamix Pharmaceuticals Ltd. Business Overview
11.3.3 Foamix Pharmaceuticals Ltd. Genital Herpes Research and Development Pipeline Introduction
11.3.4 Foamix Pharmaceuticals Ltd. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.3.5 Foamix Pharmaceuticals Ltd. Recent Development
11.4 Genocea Biosciences, Inc.
11.4.1 Genocea Biosciences, Inc. Company Detail
11.4.2 Genocea Biosciences, Inc. Business Overview
11.4.3 Genocea Biosciences, Inc. Genital Herpes Research and Development Pipeline Introduction
11.4.4 Genocea Biosciences, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.4.5 Genocea Biosciences, Inc. Recent Development
11.5 GenVec, Inc.
11.5.1 GenVec, Inc. Company Detail
11.5.2 GenVec, Inc. Business Overview
11.5.3 GenVec, Inc. Genital Herpes Research and Development Pipeline Introduction
11.5.4 GenVec, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.5.5 GenVec, Inc. Recent Development
11.6 Immune Design Corp.
11.6.1 Immune Design Corp. Company Detail
11.6.2 Immune Design Corp. Business Overview
11.6.3 Immune Design Corp. Genital Herpes Research and Development Pipeline Introduction
11.6.4 Immune Design Corp. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.6.5 Immune Design Corp. Recent Development
11.7 Immunovaccine, Inc.
11.7.1 Immunovaccine, Inc. Company Detail
11.7.2 Immunovaccine, Inc. Business Overview
11.7.3 Immunovaccine, Inc. Genital Herpes Research and Development Pipeline Introduction
11.7.4 Immunovaccine, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.7.5 Immunovaccine, Inc. Recent Development
11.8 Mymetics Corporation
11.8.1 Mymetics Corporation Company Detail
11.8.2 Mymetics Corporation Business Overview
11.8.3 Mymetics Corporation Genital Herpes Research and Development Pipeline Introduction
11.8.4 Mymetics Corporation Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.8.5 Mymetics Corporation Recent Development
11.9 NanoBio Corporation
11.9.1 NanoBio Corporation Company Detail
11.9.2 NanoBio Corporation Business Overview
11.9.3 NanoBio Corporation Genital Herpes Research and Development Pipeline Introduction
11.9.4 NanoBio Corporation Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.9.5 NanoBio Corporation Recent Development
11.10 NanoViricides, Inc.
11.10.1 NanoViricides, Inc. Company Detail
11.10.2 NanoViricides, Inc. Business Overview
11.10.3 NanoViricides, Inc. Genital Herpes Research and Development Pipeline Introduction
11.10.4 NanoViricides, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.10.5 NanoViricides, Inc. Recent Development
11.11 PaxVax
11.11.1 PaxVax Company Detail
11.11.2 PaxVax Business Overview
11.11.3 PaxVax Genital Herpes Research and Development Pipeline Introduction
11.11.4 PaxVax Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.11.5 PaxVax Recent Development
11.12 Profectus BioSciences, Inc.
11.12.1 Profectus BioSciences, Inc. Company Detail
11.12.2 Profectus BioSciences, Inc. Business Overview
11.12.3 Profectus BioSciences, Inc. Genital Herpes Research and Development Pipeline Introduction
11.12.4 Profectus BioSciences, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.12.5 Profectus BioSciences, Inc. Recent Development
11.13 Sanofi Pasteur SA
11.13.1 Sanofi Pasteur SA Company Detail
11.13.2 Sanofi Pasteur SA Business Overview
11.13.3 Sanofi Pasteur SA Genital Herpes Research and Development Pipeline Introduction
11.13.4 Sanofi Pasteur SA Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.13.5 Sanofi Pasteur SA Recent Development
11.14 Spider Biotech
11.14.1 Spider Biotech Company Detail
11.14.2 Spider Biotech Business Overview
11.14.3 Spider Biotech Genital Herpes Research and Development Pipeline Introduction
11.14.4 Spider Biotech Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.14.5 Spider Biotech Recent Development
11.15 Starpharma Holdings Limited
11.15.1 Starpharma Holdings Limited Company Detail
11.15.2 Starpharma Holdings Limited Business Overview
11.15.3 Starpharma Holdings Limited Genital Herpes Research and Development Pipeline Introduction
11.15.4 Starpharma Holdings Limited Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.15.5 Starpharma Holdings Limited Recent Development
11.16 Vaccibody AS
11.16.1 Vaccibody AS Company Detail
11.16.2 Vaccibody AS Business Overview
11.16.3 Vaccibody AS Genital Herpes Research and Development Pipeline Introduction
11.16.4 Vaccibody AS Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.16.5 Vaccibody AS Recent Development
11.17 Vaxart, Inc.
11.17.1 Vaxart, Inc. Company Detail
11.17.2 Vaxart, Inc. Business Overview
11.17.3 Vaxart, Inc. Genital Herpes Research and Development Pipeline Introduction
11.17.4 Vaxart, Inc. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.17.5 Vaxart, Inc. Recent Development
11.18 Vical Incorporated.
11.18.1 Vical Incorporated. Company Detail
11.18.2 Vical Incorporated. Business Overview
11.18.3 Vical Incorporated. Genital Herpes Research and Development Pipeline Introduction
11.18.4 Vical Incorporated. Revenue in Genital Herpes Research and Development Pipeline Business (2018-2023)
11.18.5 Vical Incorporated. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AiCuris GmbH & Co. KG
AlphaVax, Inc.
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Immune Design Corp.
Immunovaccine, Inc.
Mymetics Corporation
NanoBio Corporation
NanoViricides, Inc.
PaxVax
Profectus BioSciences, Inc.
Sanofi Pasteur SA
Spider Biotech
Starpharma Holdings Limited
Vaccibody AS
Vaxart, Inc.
Vical Incorporated.
听
听
*If Applicable.
